Feb 24, 2026 04:29PM Supernus Pharma (SUPN) Misses Q4 EPS by 48c, provides guidance

Feb 9, 2026 11:15AM Lunai Bioworks outlines three revenue engines in shareholder letter

Jan 9, 2026 07:01AM Supernus Pharmaceuticals (SUPN) Reiterated at Market Outperform by Cantor Fitzgerald

Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note

Dec 19, 2025 07:48AM Supernus Pharmaceuticals (SUPN) PT Raised to $55 at Stifel: Portfolio 'Well-Rounded'

Nov 5, 2025 10:16AM Supernus Pharmaceuticals (SUPN) PT Raised to $50 at Stifel

Nov 4, 2025 05:14PM Supernus Pharma (SUPN) Misses Q3 EPS by 94c

Oct 29, 2025 06:14AM BofA Securities Starts Supernus Pharmaceuticals (SUPN) at Buy

Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'

Oct 23, 2025 06:35AM Supernus Pharmaceuticals (SUPN) PT Raised to $60 at TD Cowen

Oct 17, 2025 07:25AM Piper Sandler on Supernus Pharmaceuticals (SUPN): 'Favorable Feedback On Onapgo From Expert Call'

Oct 9, 2025 12:19AM Piper Sandler Upgrades Supernus Pharmaceuticals (SUPN) to Overweight

Sep 30, 2025 06:51AM Supernus Pharmaceuticals (SUPN) PT Raised to $63 at Cantor Fitzgerald

Sep 17, 2025 04:30PM Biogen gets European approval for postpartum depression treatment

Aug 29, 2025 06:55AM Supernus Pharmaceuticals (SUPN) PT Raised to $40 at Piper Sandler

Aug 6, 2025 10:26AM Supernus Pharmaceuticals (SUPN) PT Raised to $43 at Stifel

Aug 5, 2025 04:42PM Supernus Pharma (SUPN) Misses Q2 EPS by 8c, provides guidance

Jul 30, 2025 07:43AM Cantor Fitzgerald Upgrades Supernus Pharmaceuticals (SUPN) to Overweight

Jul 28, 2025 08:25AM Supernus gets regulatory clearance for Sage acquisition

Jun 17, 2025 09:13AM Piper Sandler on Supernus Pharmaceuticals (SUPN): Sage Purchase A Head-Scratcher

Jun 17, 2025 06:42AM Cantor Fitzgerald Reiterates Neutral Rating on Supernus Pharmaceuticals (SUPN)

Jun 16, 2025 07:01AM Supernus Pharma (SUPN) to Acquire Sage Therapeutics (SAGE)

May 6, 2025 04:35PM Supernus Pharma (SUPN) Misses Q1 EPS by 58c, Beats on Revenue

Feb 26, 2025 09:08AM Cantor Fitzgerald Reiterates Neutral Rating on Supernus Pharmaceuticals (SUPN)

Feb 25, 2025 04:03PM Supernus Pharma (SUPN) Misses Q4 EPS by 6c

Feb 19, 2025 12:31AM Cantor Fitzgerald Downgrades Supernus Pharmaceuticals (SUPN) to Neutral

Feb 18, 2025 04:26PM Supernus Pharma (SUPN) Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

Feb 4, 2025 11:28AM Stifel Reiterates Hold Rating on Supernus Pharmaceuticals (SUPN)

Feb 4, 2025 11:19AM Supernus Pharmaceuticals (SUPN) PT Raised to $44 at TD Cowen

Feb 4, 2025 09:02AM Supernus Pharma (SUPN) Announces FDA Approval of ONAPGO for Parkinson’s Disease

Jan 27, 2025 08:00AM Supernus Pharma (SUPN) Announces Label Update for Qelbree

Nov 4, 2024 04:18PM Supernus Pharma (SUPN) Tops Q3 EPS by 25c, updates guidance

Oct 31, 2024 04:11PM Supernus Pharma (SUPN) Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data

Oct 18, 2024 08:37AM TD Cowen Reiterates Buy Rating on Supernus Pharmaceuticals (SUPN)

Oct 18, 2024 07:48AM Piper Sandler Reiterates Neutral Rating on Supernus Pharmaceuticals (SUPN)

Oct 17, 2024 04:05PM Supernus Pharma (SUPN) Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Sep 10, 2024 05:11PM Piper Sandler Downgrades Supernus Pharmaceuticals (SUPN) to Neutral

Aug 19, 2024 07:01AM Supernus Pharma (SUPN) Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA